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In contrast to the extraordinary body of knowledge gained over the past three decades on the virology,
pathogenesis, and immunology of HIV-1 infection, innate sensors that detect HIV-1 had remained elusive until
recently. By virtue of integration, retroviridae makes up a substantial portion of our genome. Thus, immune
strategies that deal with endogenous retroviruses are, by necessity, those of self-preservation and not of
virus elimination. Some of the principles of such strategies may also apply for defense against exogenous
retroviruses including HIV-1. Here, I highlight several sensors that have recently been revealed to be capable
of recognizing distinct features of HIV-1 infection, while taking into account the host-retrovirus relationship
that converges on avoiding pathogenic inflammatory consequences.Introduction
The immune system protects the host from infections by either
eliminating the invading pathogens or by reducing the negative
impact of infections on host fitness (Medzhitov et al., 2012).
Conversely, pathogens vary in their impact on host fitness,
with highly virulent pathogens on one end of the spectrum and
beneficial microbes essential for many of the host develop-
mental and physiological processes on the other end of the
spectrum. Though this notion has been best appreciated for
bacteria, it also applies to other microorganisms colonizing the
host, including viruses. Humans are continuously infected by
a variety of viruses that do not appear to be associated with
any obvious pathological outcomes (Virgin et al., 2009) and
perhaps even providing some unrecognized benefits. The
extreme example of an intimate association between microor-
ganisms and human hosts are endogenous retroviruses, which
form a significant fraction of the human genome. Whatever
were the reasons for their ‘‘colonization’’ of our genome, elimina-
tion of endogenous retroviruses is no longer an option. Indeed,
the only outcome of an immune response against endogenous
retroviruses would be a swift destruction of the host. Conse-
quently, our immune system is left with no other choice but to
learn to live in peace with the genomic intruders. This, in turn,
implies that the human hosts have to tolerate the presence of
endogenous retroviruses and refrain from an overt immune
response against them.
Although endogenous retroviruses are an extreme case, some
of the same strategies may apply to exogenous retroviruses
because they all share an integration step, thereby at least
transiently becoming part of the host. Thus, one common theme
in immunity to retroviruses is the development of a multitude of
mechanisms that prevent overt immune reactions directed at
them. This may be particularly relevant to our understanding of
immunity to HIV-1. This strategy is well appreciated in the case
of host immunity to commensal bacteria in the gut, where
‘‘beneficial’’ microbes are the ones that suppress inflammatory
responses, whereas ‘‘detrimental’’ bacteria are particularly
prone to eliciting a vigorous immunity that can result in colitis
and other inflammatory diseases. This notion becomes a central
theme of how we might make sense of innate responses to
HIV-1, because HIV-1 is a member of the retroviridae, andalthough it has unique pathogen associated molecular patterns
(PAMPs) that can alert the human cells of invasion, it also falls
under the multitude of host mechanisms that prevent overt
immune reaction to retroviruses in general. Here, I will discuss
innate sensors for HIV-1 and other retroviruses that operate in
different cell types, in the context of host strategies that have
evolved to avoid immune stimulation against retroviruses, and
by taking into consideration the cell-to-cell transmission mecha-
nism of HIV-1. The consequences of host antiviral strategies and
virus manipulation of host innate immune responses on the
outcome of HIV-1 infection and pathogenesis will be discussed.
Innate HIV-1 Sensors
Viruses are detected by the innate immune system primarily by
recognition of viral nucleic acids. There are two general modes
of sensing viral nucleic acids: the first is the detection of viral
genomes present within the virions, the second is detection of
nucleic acids produced during viral replication. An example of
the first mode of recognition is the Toll-like receptors (TLRs)
expressed in the endosomes, which detect nucleic acids of the
genomes associated with the virions. Plasmacytoid dendritic
cells (pDCs) utilize TLR7 and TLR9 to recognize single-stranded
RNA (ssRNA) and double-stranded DNA (dsDNA) viruses,
respectively (Pichlmair and Reis e Sousa, 2007). This type of
recognition usually does not require productive infection of
pDC by viruses. On the other hand, viral sensors present in the
cytosol recognize viral nucleic acids generated upon replication.
This mode of recognition is engaged only following viral infection
of the cell. Thus, infected cells recognize viral RNA through RIG-
I-like receptors (RLR) (Takeuchi and Akira, 2008) and viral DNA
through a set of receptors including DAI, IFI16, and AIM2
(Thompson et al., 2011). Engagement of these sensors leads
to transcriptional activation of proinflammatory cytokines and
type I interferons (IFNs). Type I IFNs bind to IFN-abR on infected
and neighboring cells and transduce signals that activate
expression of hundreds of IFN-stimulated genes (ISGs) that act
in concert to block virus replication and spread (Stetson and
Medzhitov, 2006).
HIV-1 predominantly infects and replicates in CD4 T cells.
In addition, HIV-1 infects a small percentage of CD4+ dendritic
cells (DCs) and macrophages. Recent studies highlight distinctImmunity 37, September 21, 2012 ª2012 Elsevier Inc. 389
Table 1. Innate HIV-1 Sensors and Effectors
Type Sensor Ligand Signaling Pathway Location Cell Type
General TLR7 ssRNA IRF7, NF-kB Endosome pDC, B
TLR8 ssRNA IRF7, NF-kB Endosome DC
Unknown DNA sensor ISD DNA
(RT product)
IRF3 Cytosol Many cell types (except for
transformed cells)
Species-specific CypA Capsid IRF3 Cytosol DC
TRIM5, TRIM5-CypA Capsid AP-1, NF-kB Cytosol DC, myeloid cell
Type Effectors/Function Target or Substrate End Results Location Cell Type
General SAMHD1/
triphosphohydrolase
dNTPs dNs + ppp Cytosol DC, macrophage
TREX1/exonuclease ssDNA dNMPs Cytosol Many cell types including DC,
macrophage, CD4 T, fibroblast.
APOBEC3a/Cytidine
deaminase
Negative
sense DNA
Hypermutation Virion Cytosol CD4 T, macrophage
IFN-inducible in CD4 T,
macrophage, hepatocytes
Tetherin Budding
membrane
Block virion
release
Cell surface Type I IFN inducible in many
cell types.
Species-specific TRIM5 Capsid Capsid disruption Cytosol CD4 T, macrophage
Abbreviations; APOBEC, apolipoprotein B mRNA-editing, enzyme-catalytic, polypeptide-like; dNTP, deoxynucleoside triphosphate; dNMP,
deoxynucleoside monophosphate; ISD, interferon-stimulatory DNA; ppp, triphosphate; ssDNA, single-stranded DNA.
aDetailed functions of effectors APOBEC3 and tetherin are described elsewhere (Blanco-Melo et al., 2012).
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recognize HIV-1 in the endosomes without becoming produc-
tively infected. Important in this regard is the fact that HIV-1
transmission between cells occurs through the virological
synapse (Jolly and Sattentau, 2004). Infected cells use virolog-
ical synapse (Hu¨bner et al., 2009) and filopodia to transmit
HIV-1 virions to target cells (Sherer et al., 2007). Based on this
new level of understanding of viral transmission mechanism, in
some cases, we must rethink the way we interpret innate recog-
nition of HIV-1 and other retroviruses (Jolly, 2011). Recent
studies reveal innate sensors that recognize PAMPs associated
with HIV-1 or those that are generated during HIV-1 infection
(Table 1). Some of these sensors recognize nucleic acids that
are associatedwith retroviral infection in general, whereas others
recognize HIV-1 viral proteins in species-specific manner. The
engagement of each sensor results in distinct signaling path-
ways, and they appear to operate in distinct cell types.
Toll-like Receptor 7 Detects Cell-free and Cell-
Associated HIV-1
TLR7 is expressed by two specialized cell types in humans. It is
constitutively expressed by pDCs, which are a rare population of
leukocytes that are specialized in detection of a wide variety of
viruses (Gilliet et al., 2008). Although expressed constitutively,
TLR7 expression is greatly enhanced by type I IFNs in B cells
(Marshak-Rothstein and Rifkin, 2007). TLR7 recognizes ssRNA
within the endosome (Diebold et al., 2004; Heil et al., 2004;
Lund et al., 2004). Recognition of cell-free HIV-1 by TLR7 in
human pDCs requires attachment and endocytosis but not the
downstream infection stages, including fusion, reverse transcrip-
tion, integration, or nucleocapsid production (Beignon et al.,
2005). HIV-1 traffics to the early endosome and induces persis-
tent IFN-a stimulation in pDCs (O’Brien et al., 2011). Although
purified HIV-1 virions are capable of stimulating human pDC at390 Immunity 37, September 21, 2012 ª2012 Elsevier Inc.very high concentrations (Fitzgerald-Bocarsly and Jacobs,
2010), HIV-1 infected CD4 T cells are much more potent at stim-
ulating human pDCs following cell contact (Lepelley et al., 2011).
Interestingly, nonfusogenic env mutant HIV-1 elicits much less
IFN-a compared to WT HIV-1, indicating that innate recognition
of HIV-1-infected cells by pDCs depends on fusion of the virus.
Thus, cell-free HIV-1 and cell-associated HIV-1 may be recog-
nized by separate pathways converging on TLR7 (Figure 1).
Other retroviruses including murine leukemia virus (MLV) and
mouse mammary tumor virus (MMTV) also require TLR7 and
MyD88, an adaptor required for TLR signaling, for in vivo recog-
nition and stimulation of humoral immune responses (Browne
and Littman, 2009; Kane et al., 2011). TLR7-dependent antibody
responses are elicited by live or UV-irradiated MLV, but not heat
inactivatedMLV, indicating that entry of the virus, but not replica-
tion, is required to stimulate TLR7 (Kane et al., 2011). These data
are consistent with the requirement for fusion of HIV-1 in recog-
nition of infected cells by pDCs (Lepelley et al., 2011). The exact
nature of HIV-1 ligand for TLR7 is unknown. If fusion of the HIV-1
must precede recognition (Lepelley et al., 2011), a mechanism
must exist to deliver cytosolic viral RNA into the endosomewhere
TLR7 resides. Other ssRNA viruses are recognized through TLR7
upon delivery of cytosolic RNA replication intermediates through
autophagy (Lee et al., 2007). In line with this, knockdown of
Atg7 by small interfering RNA (siRNA) in human pDCs results in
impaired TLR7-dependent IFN-a secretion in response to
HIV-1 (Zhou et al., 2012). Therefore, one can speculate that auto-
phagy may be used to transport cytosolic HIV-1 capsid contain-
ing ssRNA into the endosome where TLR7 resides (Figure 1).
However, HIV-1 inhibits autophagy (Zhou and Spector, 2008)
through env binding to its receptor, inducing mTOR activation
and leading to blockade of autophagy in target cells (Blanchet
et al., 2010). Towhat extent TLR7 recognition of HIV-1 is inhibited
by env-mediated mTOR activation remains to be determined.
Figure 1. Innate Recognition of HIV-1 by
Plasmacytoid Dendritic Cells
(A) Cell-free virus is taken up by pDCs via endo-
cytosis and is recognized by TLR7. HIV-1 env
binds to CD4molecule expressed on human pDCs
and trigger signaling and endocytosis. The ssRNA
genome inside the virion stimulates TLR7 upon
degradation of envelope and capsid by endo-
somal hydrolases.
(B) HIV-1-infected CD4 T cells are recognized by
pDCs in a process that involves endocytosis and
fusion. Based on the HIV-1 cell-to-cell trans-
mission mechanism involving filopodia formation
and transport of virions via the virological synapse,
the pDCs likely have access to many more virions
for recognition through direct cell contact. Once
HIV-1 fuses, the ssRNA genomemust gain access
to endosomes to activate TLR7.
(C) The speculative model is that viral PAMP is
introduced to endosomal TLR7 via autophagy.
Once TLR7 binds to ssRNA, it signals through
MyD88 and IRF7 to trigger activation of type I IFN
and cytokine genes, which play critical roles in
innate immunity and pathogenesis of HIV-1.
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TLR8 is expressed by DCs but not pDCs in humans and recog-
nizes HIV-1-derived ssRNA (Heil et al., 2004). DCs also express
the C-type lectin DC-SIGN, which binds to env and facilitates
transmission of HIV-1 to CD4 T cells (Geijtenbeek et al., 2000).
Although themajority of humanDCs are not productively infected
with HIV-1 strains in vitro, a small fraction (1%–3%) of DCs and
pDCs do become infected (Smed-So¨rensen et al., 2005). On
examination of productively infected DCs, paradoxically, TLR8
stimulationbyHIV-1promotesHIV-1 replication inDCs (Gringhuis
et al., 2010). Once HIV-1 provirus is integrated into host genome,
signals from TLR8 initiate HIV transcription by RNA polymerase II
through the recruitment of cyclin-dependent kinase-7, while
signals from DC-SIGN lead to transcriptional elongation through
the recruitment of P-TEFb (positive transcription elongation
factor b). Together, TLR8 and DC-SIGN signaling promotes full
transcriptional program for HIV-1 genome and production ofImmunity 37, SeHIV-1proteins. The immunological conse-
quence of productive infection of DCs by
HIV-1 is discussed below.
Cytosolic DNA Sensor Hidden
by TREX1
Within HIV-1 infected cells, an unknown
DNA sensor detects the presence of com-
plementary DNA (cDNA) and DNA inter-
mediates generated by the RT (Figure 2).
The sensor triggers activation of IFN-b
gene through STING and IRF3 (Table 1).
Despite great interest and effort in the
field, the putative sensor for DNA in the
cytosol responsible for recognizing RT
products has not yet been identified and
may consist of more than one sensor.
The presence and activity of DNA sensor
for retroviruses were unknown until re-
cently, because they are concealed bythe host exonuclease, TREX1 (Stetson et al., 2008; Yan et al.,
2010). TREX1 is a 30-50 DNA exonuclease that cleaves ssDNA
fragments derived from endogenous retroelements (Stetson
et al., 2008). TREX1 represents a good example of how humans
have evolved to deal with endogenous retroviruses—by devising
ways to avoid generating inflammatory responses against them.
Mutations in TREX1 are associated with Aicardi-Goutie`res
syndrome and chilblain lupus, which results from accumulation
of endogenous retroelements and overstimulation of a cytosolic
DNA sensor (Stetson et al., 2008). This sensor is expressed by
many cell types including macrophages, DCs, fibroblasts, and
CD4 T cells (Stetson et al., 2008; Yan et al., 2010). In the absence
of TREX1, enough ligand for DNA sensor accumulates in HIV-1
infected cells to turn on type I IFN genes. In infected human
CD4 T cells, HIV-1 is efficiently controlled when TREX1 is
knocked down by siRNA, presumably through the IFNs secreted
by the infected cells (Yan et al., 2010) (Figure 3).ptember 21, 2012 ª2012 Elsevier Inc. 391
Figure 2. Innate Recognition of HIV-1 by
Dendritic Cells and Macrophages
HIV-1 env binds to CD4 and CCR5 expressed on
DCs and macrophages and enables viral fusion.
(A) Capsid lattice in the cytosol is bound by
TRIM5a and TRIM5-CypA fusion proteins (in
certain nonhuman primates) via the PRYSPRY
or the CypA domains, respectively, in species-
specific manner. This activates E3 ubiquitin ligase
function of TRIM5a, to catalyze synthesis of
free ubiquitin chains that activate TAK1 kinase
complex leading to AP-1 and NF-kB activation.
HIV-1 capsid is only weakly recognized by human
TRIM5a. Within the subviral particle, cDNA syn-
thesis on HIV-1 genomic RNA begins.
(B) SAMDH1 blocks reverse transcription at the
minus strand strong stop DNA stage, by limiting
the availability of free dNTPs needed for further
cDNA synthesis. However, this is countered by
Vpx, which induces SAMDH1 degradation. HIV-1
does not encode Vpx, and thus human DCs are
not productively infected.
(C) Defective viral RT-generated DNA products
are sensed by a cytosolic DNA sensor. However,
accumulation of such DNA intermediates is
blocked by TREX1, which degrades such product
via its 30-50 exonuclease activity.
(D) By introducing Vpx, productively infected DCs
stimulate type I IFN synthesis and are properly
activated for T cell stimulation, through sensing
of de novo synthesized viral capsid via CypA.
STING and IRF3 are required to induce type I
IFNs downstream of the DNA sensor and the
CypA pathways. Viral antihost molecules, innate
sensors, and innate effectors are color coded as
indicated.
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may be detrimental, leading to CD4 T cell decline, a hallmark of
HIV-1 pathogenesis. Greene and colleagues have shown that
accumulation of abortive RT intermediates in resting CD4
T cells following contact with HIV-1 infected cells induces
apoptotic and inflammatory programs in nonproductively in-
fected CD4 T cells (Doitsh et al., 2010). Consequently, cytosolic
DNA triggers death of ‘‘bystander’’ abortively infected CD4
T cells through the induction of apoptosis and inflammasome
activation (Figure 3). ThecDNAproducts in theabortively infected
CD4 T cells are presumably not degraded sufficiently by TREX1,
possibly because the substrates overwhelm the capacity of
TREX1. In addition to possibly stimulating caspase-3 (apoptosis)
and caspase-1 (pyroptosis) death pathways, DNA sensor
activation in the nonpermissive CD4 T cells also leads to IFN-
b induction (Doitsh et al., 2010). Thus, it is possible that the dying
bystander CD4 T cells may be a source of type I IFNs in HIV-1
infected individual, especially during the later phase leading to
AIDS (von Sydow et al., 1991). As discussed below, chronic
secretion of type I IFNs is associated with AIDS progression.
Cyclophilin A in DCs Senses HIV-1 Capsid But Is Masked
by SAMHD1
As discussed above, human DCs are not effectively infected by
HIV-1. Recent studies revealed that this is because DCs express392 Immunity 37, September 21, 2012 ª2012 Elsevier Inc.SAMHD1, which arrests the virus infec-
tion at the stage of minus strand strong
stop DNA (Figure 2). SAMHD1 hydrolyzesintracellular deoxynucleoside triphosphates (dNTPs), lowering
their concentrations and preventing synthesis of the viral DNA
byRT in DCs andmacrophages (Goldstone et al., 2011) (Table 1).
Lentiviruses of the HIV-2 and SIV (simian immunodeficiency
virus) sooty mangabey lineage express Vpx, which promotes
ubiquitination and degradation of SAMHD1 through recruitment
of multisubunit cullin 4A-ring E3 ubiquitin ligase CRL4 (Hrecka
et al., 2011; Laguette et al., 2011). Curiously, HIV-1 does not
encode Vpx, rendering it incapable of productively infecting
DCs. A sensor capable of inducing robust type I IFN responses
was discovered by lifting SAMHD1-mediated restriction of
HIV-1 in human DCs through introduction of Vpx (Manel et al.,
2010). This sensor, cyclophilin A (CypA), is a peptidylpropyl
isomerase that is expressed in cytosol. It binds to de novo
synthesized HIV-1 capsid and activates IRF3-dependent induc-
tion of type I IFN genes (Manel et al., 2010) (Figure 2). Strikingly,
direct infection of DCs in the presence of Vpx enabled expres-
sion of costimulatory molecules and activation of CD4 T cells
in the presence of anti-CD3 antibody. Moreover, HIV-1 infected
DCs inhibited trans-enhancement of CD4 T cell infection through
secretion of type I IFNs. Whether the capsid itself is the PAMP
that activates IRF3 through CypA or whether CypA intersects
with nucleic acid recognition pathway to induce type I IFNs
remains an intriguing mystery (Manel and Littman, 2011). Of
note, even though CD4 T cells are naturally productively infected
Figure 3. Innate Recognition of HIV-1 in
CD4 T Cells
CD4 T cells are either productively infected or
nonpermissive for HIV-1 replication.
(A) In permissive CD4 T cells, HIV-1 recognition
by cytosolic DNA sensor is blocked by TREX1
degradation of RT intermediate DNA products.
(B) In CD4 T cells that are abortively infected, HIV-
1 triggers death by possibly inducing apoptosis
and inflammasome activation (pyroptosis). These
pathways of cell death are mediated by a cytosolic
DNA sensor that is stimulated by accumulation of
defective RT products.
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main sensor of HIV-1 appears to be an unknown DNA sensor,
because TREX1 knockdown results in enhanced IFN production
by HIV-1 infection (Yan et al., 2010) (Figure 3).
Why is Vpx missing in HIV-1? Certain SIV strains possess Vpr
that can efficiently degrade SAMHD1, and this preceded the
evolutionary emergence of Vpx (Lim et al., 2012). However,
phylogenetic analysis revealed that Vpr of HIV-1 or its predeces-
sors (chimpanzee SIV) never possessed the ability to degrade
SAMHD1. Thus, lineage of lentiviruses preceding HIV-1 never
acquired the ability to degrade SAMHD1, and this may have
served HIV-1 well, by disabling DCs from CD4 stimulation and
enabling DCs for enhanced trans-infection of CD4 T cells (Manel
and Littman, 2011).
TRIM5a Senses Lentiviral Capsid Lattice-Mismatch
in Human TRIM5a and HIV-1 Capsid
TRIM5a is well known for its ability to restrict retroviruses
in species-specific manner (Joly et al., 1991; Stremlau et al.,
2004). TRIM5a binds to incoming retroviral capsid via its
PRYSPRY domain and promotes disassembly before comple-
tion of reverse transcription (Gru¨tter and Luban, 2012) (Figure 2).
Recent study demonstrates that TRIM5-dependent restriction
relies on signal transduction. TRIM5a recognition of capsid
lattice stimulates its E3 ubiquitin ligase function, to catalyzeImmunity 37, Sesynthesis of free K63-ubiquitin chains
that activate TAK1 kinase complex (Pertel
et al., 2011). TAK1 activation by TRIM5a
promotes AP-1 and NF-kB signaling in
DCs. Ectopic expression of TRIM5a is
not sufficient to induce transcription of
IFN-b but together with IRF3 overex-
pression, enhances IFN-b production
and mediates antiviral effects (Figure 2).
TRIM5a-CypA fusion protein from owl
monkey also stimulates the same TAK1
pathway as the full length TRIM5a,
even though TRIM5a-CypA lacks the
PRYSPRY domain (Pertel et al., 2011),
indicating that the RING domain contain-
ing the E3 Ub ligase activity is essential
for signaling-dependent antiviral activity
of TRIM5a. The same study demon-
strated that TRIM5a is involved in innate
signaling from TLR4 in the absence of
capsid recognition. Thus, TRIM5a can actdownstream of TLR4 signaling to enhance Jun and NF-kB sig-
naling in macrophages and DCs. However, in lentivirus-infected
cells, the presence of the stimulatory capsid structure in the
cytosol promotes more efficient lattice formation by TRIM5a
(Gru¨tter and Luban, 2012), enhancing its enzymatic activity to
promote signaling and to block infection prior to reverse tran-
scription. Because human TRIM5a is only capable of weak bind-
ing to HIV-1 capsid and restricting the virus (Joly et al., 1991;
Stremlau et al., 2004), innate sensor activity of TRIM5a against
HIV-1 is expected to be limited. It would be interesting to deter-
mine whether TRIM5a contributes to innate immunity against
HIV-1 by acting downstream of TLR7-mediated recognition,
akin to the pathway demonstrated for TLR4 (Pertel et al., 2011).
Possible Interplay between Retroviral Innate Sensor
Pathways
The host sensing pathways of viral capsid and DNAmay bemore
intimately linked than meets the eye. As suggested by Littman
and colleagues, capsid-induced CypA stimulation of IRF3 may
involve the DNA sensor (Manel and Littman, 2011). In addition,
as mentioned above, in all species of New World owl monkeys,
TRIM5a is expressed as a fusion protein between the TRIM5a
N-terminal domain and the CypA full-length protein replacing
the PRYSPRY domain of TRIM5a. This fusion was mediated by
LINE1 retrotransposition of a CypA cDNA into the TRIM5 locusptember 21, 2012 ª2012 Elsevier Inc. 393
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fusion event generated TRIM5a-CypA chimera in some Old
World primate species, Asian macaques (Newman et al.,
2008). Asmentioned above, this fusion protein is capable of sup-
porting TAK1 activation when the CypA portion is engaged by
retroviral capsid lattice (Pertel et al., 2011). As long as the
TRIM5a domains at the N terminus do not interfere with CypA
function, it is expected that such a fusion protein would also
be capable of activating IRF3 through the pathway described
by Manel et al. (2010). Of note, anti-HIV-1 activity of an engi-
neered human TRIM5a fused to human CypA is more effective
than that of the well-characterized rhesus TRIM5a, in blocking
HIV-1 infection in primary CD4 T cells and macrophages (Neagu
et al., 2009). Perhaps given sufficient time and selective pres-
sure, a similar fusion protein could naturally arise and become
selected for in humans in HIV-1 endemic areas. The evolution
of TRIM5-CypA fusion proteins in Old World monkeys revealed
that the fusion protein acquired several mutations along the way,
which enhanced restriction to particular viruses at the cost of
broad coverage of lentiviruses (Ylinen et al., 2010). The fasci-
nating convergent evolution of TRIM5-CypA in New World
monkeys and Old World monkeys suggests that this fusion
protein conferred evolutionary advantage to certain highly path-
ogenic lentiviruses in the respective species over the pre-
existing TRIM5a proteins. It is tempting to speculate that the
advantage included synergism between the innate sensor
pathway of TRIM5a and CypA.
Innate Responses Elicited by HIV-1 in Productively
Infected CD4 T Cells
As discussed above, virtually all cell intrinsic innate recognition
pathways for HIV-1 are disabled by the host or by the virus. In
addition, HIV-1 induces a global disruption of innate signaling
pathways in infected cells by degrading interferon-regulatory
factor 3 (IRF3) (Doehle et al., 2009). Not surprisingly, infection
of CD4 T cells with HIV-1 does not result in typical IFN signatures
(Pankiv et al., 2007). Compendium analysis of genes regulated
by various stimuli revealed that HIV-1 infection induces very
specific changes that are distinct from heat shock stress-
response or IFN response pathways. In contrast, gene profiles
induced by type I IFNs and influenza virus infection are mostly
overlapping (van ’t Wout et al., 2003). Proteomic analysis of
HIV-1-infected CD4 T cells revealed a differential expression
of proteins in select biological pathways, including ubiquitin-
conjugating enzymes, carrier proteins in nucleocytoplasmic
transport, cyclin-dependent kinase in cell-cycle progression,
and pyruvate dehydrogenase of the citrate cycle pathways
but notably missing in IFN signaling or induction pathways
(Chan et al., 2007). However, neither mechanism nor conse-
quences of such distinct gene profiles induced byHIV-1 infection
in target CD4 T cells is understood. Whether similar genes are
induced by endogenous retroviruses and if so, whether the
consequences of turning on such sets of genes assist host
tolerance mechanisms for coexistence with endogenous retrovi-
ruses is of interest for future studies. Understanding the unique
genomic and proteomic signatures associated with retrovirus
infection in target cells may provide the key to unlocking the
mystery of the ‘‘host appropriate’’ immune response to this
group of viruses, and may teach us ways in which we might394 Immunity 37, September 21, 2012 ª2012 Elsevier Inc.mimic such responses to avoid pathologic consequences of
HIV-1 infection.
Mucosal Barrier as Innate Shield against HIV-1
HIV-1 transmission is extremely inefficient in the female genital
mucosa. Successful transmission via heterosexual penile-
vaginal exposure occurs only 1 in 100 or 1,000 exposures
(Powers et al., 2008), whereas male circumcision and existing
genital ulcers can dramatically decrease or increase the infection
rate, respectively. In contrast, heterosexual anal intercourse
between serodiscordant couples has a transmission rate of 1
for every 3–10 episodes. This rate is similar to the transmission
risk in penile-anal intercourse between men who have sex with
men (Vittinghoff et al., 1999). This highlights the protective barrier
provided by the vaginal mucosa compared to rectal mucosa.
The vaginal tract is specialized to provide protective mecha-
nisms including its thick epithelial layer, mucus, antimicrobial
peptides, low pH, and Lactobacillus-rich endogenous micro-
biota (Iwasaki, 2010). Instead, HIV-1 enters likely from the endo-
cervix, where epithelial layer is single cell thick and is more prone
to disruption (Haase, 2010). The rectal mucosa is covered by
a single layer of columnar epithelial cells and contains abundant
lymphoid follicles that contain viral target cells (Ribeiro Dos
Santos et al., 2011). What clinical approaches might we take in
the future to deal with the lack of a protective mucosal barrier
in the rectum? Aside from the existing approaches including
the use condoms and other safe sex practices, inclusion of anti-
viral agents or molecules that fortify the epithelial barrier in the
lubricant might provide additional protection against rectal
HIV-1 exposure.
Role of Type I IFNs in Innate Defense against HIV-1
In humans acutely infectedwith HIV-1, type I IFNs are detected in
the serum starting almost immediately following infection and
until 12 days postinfection (von Sydow et al., 1991). This rise in
IFN-a is closely followed by a decline in HIV load. Although the
exact source of IFN-a is not known, pDCs are a likely candidate
as they are equipped with viral sensor TLR7 and are capable of
secreting large amount of type I IFNs and cytokines in a rapid
response to HIV-1. In addition, as described above, the TLR7
pathway is the only one that is not countered effectively by the
virus or the host for IFN synthesis. Type I IFNs induce expression
of hundreds of ISGs in responding cells, some of which can
contribute to HIV-1 restriction (Florey et al., 2011). However,
type I IFNs secreted locally by pDCs in the cervical mucosa para-
doxically may have detrimental consequences. Shortly after SIV
vaginal challenge, pDCs are recruited just beneath the cervico-
vaginal epithelial cells, likely through the action of CCL20.
Instead of suppressing virus replication, local pDC-secreted
type I IFNs and chemokines CCL3 and CCL4 can recruit viral
target CCR5+ CD4 T cells (Li et al., 2009).
As the infection progresses, blood pDC numbers decline in
HIV-1 infected patients (Chehimi et al., 2002; Soumelis et al.,
2001). At later time points of HIV-1 infection, pDC from viremic
patients produce little IFN in response to HIV-1 (Machmach
et al., 2012) presumably due to downregulation of CD4 molecule
in pDCs imposed by viremia (Barblu et al., 2012). This results in
overall decline in the plasma IFN levels in most chronically
HIV-infected patients. Moreover, high plasma titers of IFN-a
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disease progression in humans (von Sydow et al., 1991). This
is also supported by the gene profiling studies of SIV-infected
nonhuman primates that progress to AIDS (macaques) versus
those that harbor high viral titers without developing disease
(African green monkeys and sooty mangabeys). Although all
groups express similar levels of type I IFNs during the acute
infection, only the macaques retained high IFN levels in the
chronic phase of infection (Bosinger et al., 2009; Jacquelin
et al., 2009). The sustained IFN and cytokine signatures in
macaques during chronic SIV infection closely mirror responses
in humans infected with HIV-1 (Mandl et al., 2008). Therefore,
while the transient type I IFNs in serum of acutely infected
individuals may contribute to suppression of systemic level of
HIV-1, the initial cervicovaginal IFN response recruits more
target cells. On the other hand, chronic expression of IFN fuels
HIV-1 pathogenesis. How might the chronic levels of type I
IFNs in the susceptible host lead to AIDS? It is thought that
natural hosts (sooty mangabeys) are capable of removing viral
target cells through maintaining low expression of surface viral
receptors (i.e., CD4, CCR5) on T cells, both at steady state and
following lentivirus infection, whereas the central memory
T cells of the susceptible hosts upregulate CCR5, with the help
of chronic levels of IFNs, and fuel the infection of memory
T cell pool (Brenchley et al., 2010). Thus, a possible future inter-
vention against AIDS might be to minimize infection of target
cells (through blockade of viral receptors) or attenuate chronic
activation of the IFN-abR signaling, preferably in central memory
T cells. The latter approach must be carefully weighed against
the risk of infection by viruses in general, by interfering with
IFN-abR signaling.
Innate Link to Adaptive Immunity
What innate signals are needed to trigger adaptive immune
responses to retroviruses including HIV-1? Recent studies begin
to provide clues to this question, but the answer may depend on
the immunological outcome. As discussed above, in vivo studies
in mice reveal that antibody responses to murine retroviruses,
Friend murine leukemia virus (F-MLV), and MMTV require TLR7
and MyD88, as well as DCs (Browne and Littman, 2009; Kane
et al., 2011). In contrast, DC-depleted and MyD88-deficient
mice develop intact CD8 T cell responses to MLV (Browne and
Littman, 2009). In F-MLV-infected TLR7 knockout mice, B cells
upregulate CD69 and CD86 early in infection but fail to develop
into germinal center B cells (Browne, 2011). TLR7-deficient
mice also have impaired CD4 IFN-g secretion but intact CD8
T cell responses to F-MLV. Deletion of MyD88 in B cells, but
not DCs, impaired antibody response to F-MLV, but not CD4
T cell responses. Thus, different innate sensors appear to be
needed for different effector functions, namely, that TLR7 in B
cells appears to be required for antibody responses, whereas
Th1 CD4 T cell responses requires TLR7 expression in non-B
cells (likely in DCs) in response to retroviruses in mice. In con-
trast, CD8 T cell responses develop in the absence of TLR7 or
MyD88. However, the importance of these sensors in human
HIV-1 infection is not yet determined.
Can HIV-1-infected DCs prime T cell responses? In the case
of many if not all viruses, directly infected APCs are rendered
incapable of stimulating naive T cells. Viruses can inhibit everyaspect of DC biology, from their migration, activation, secretion
of cytokines, and presentation of antigens on MHC class I and
class II. HIV-1 is no exception. First, HIV-1 does not productively
infect DCs. Second, even the rare productively infected DCs
would be rendered incapable of stimulating T cells in the pres-
ence of nef, which downregulates CD80 and CD86 (Chaudhry
et al., 2005), as well as MHC class I (Kenter et al., 2009; Thurston
et al., 2009) and class II (Stumptner-Cuvelette et al., 2001). Thus,
the likely mode of T cell priming is through cross-priming of viral
antigens to naive CD8 T cells by uninfected DCs. However,
innate sensors responsible for activating DCs to cross prime
HIV-1-specific CD8 T cells remain undefined.
Amajor hurdle in DC activation of HIV-1-specific CD4 T cells is
that interaction between DCs harboring HIV-1 and cognate CD4
T cells results in robust trans-infection of CD4 T cells (Geijten-
beek et al., 2000). DC-SIGN expressed on DCs can bind HIV-1
envelope gp120 and internalize virions through endocytosis.
This endosomal location of DC-SIGN protects the virions from
degradation, and poises them for infection of CD4 T cells. In
addition, DCs andCD4 T cells form syncytia uponHIV-1 infection
(Pope et al., 1994) in the tonsil and other lymphoid tissues
(Frankel et al., 1996) that provide a breeding ground for HIV-1.
Once incorporated into syncytia, HIV-primed CD4 T cells will
not be able to escape and perform antiviral activities. Thus, in
order for DCs to successfully prime virus-specific CD4 T cells,
they would have to take up dead virus or viral antigens, while
specifically avoiding live virus, to process and present viral anti-
gens to naive CD4 T cells. This situation may be very rare but
must occur, because anti-HIV-1 CD4 T cell responses are
robustly generated in HIV-1 infected individuals. HIV-1-specific
CD4 T cells may be in fact critical in controlling HIV-1 infection
early, which impacts on the disease course. In particular, lytic
CD4 T cell phenotype at baseline (high granzyme A expression)
and CD107a degranulation phenotype during the early stages
of HIV infection (2–6 months) correlate with low viral set point
and successful control of HIV-1 infection (Soghoian et al.,
2012). Therefore, a mechanism must exist whereby DCs or
possibly other APCs sample viral antigens while avoiding infec-
tion. Identification of the antigen-presenting cell type and the
innate sensors that link HIV-1 recognition to successful priming
of virus-specific CD4 and CD8 T cells will provide key knowledge
needed to generate robust protective anti-HIV-1 immunity,
which may naturally occur in rare controllers. In addition, it is of
special interest to determine the mechanism of viral antigen
sampling and processing by the key antigen presenting cells
that accomplish these tasks without becoming infected or fused
to infected cells.
Future Perspectives
Due to the large public and private investments toward HIV-1
research, the field has experienced an explosion of discoveries
related to its virology, viral pathogenesis, and immunology of
HIV-1 infection. The basic scientific research on HIV-1 has
revealed a great deal about host cell biology, innate immunity,
and the generation of adaptive immunity, while clinical transla-
tion of the basic understanding has lead to over 20 different anti-
viral agents that are highly effective and are widely used (Deeks
et al., 2012). However, it is sobering to realize that all possible
innate sensor pathways, perhaps with the exception of TLR7,Immunity 37, September 21, 2012 ª2012 Elsevier Inc. 395
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immune system little to work with in terms of generating an early
wave of type I IFNs that can limit viral set point and improve the
course of HIV-1 disease. Some experts in the field argue that it is
the delayed activation of innate immune responses with respect
to peak viremia that sets off chronic immune activation and
progression to AIDS, and the question of whether an adaptive
immune response can be mounted against HIV is irrelevant
and should no longer be the focus of vaccine research strategies
(Benecke et al., 2012). How might one achieve rapid and robust
innate activation following HIV-1 infection that successfully sets
viral set point to lowest possible levels? Devising ways of
triggering the innate sensors to enable them to generate IFNs
and limiting virus replication early during HIV-1 infection may
provide an alternative to HIV-1 vaccine based on generating
adaptive immunity. Examples of such approach may include
knockdown of factors responsible for inhibiting innate sensor
activations, such as TREX1, SAMDH1, or introducing ‘‘cognate’’
TRIM5a for HIV-1 capsid. Identification of DNA sensor(s) that
recognize RT products in the cytosol will also provide molecular
targets for eliciting robust IFN response and adaptive immunity.
Another topic for future investigation is the possible role of
innate effectors in the generation of adaptive immunity to
HIV-1. As discussed here, innate restriction factors, SAMDH1
and TREX1, control the availability of ligands for DNA sensor
during HIV-1 infection, thereby blocking induction of innate
and adaptive immune responses. Other restriction factors
such as APOBEC3 and tetherin restrict HIV-1 by acting on
very different stages of the viral life cycle (see Blanco-Melo
et al. [2012] in this issue for in-depth description) (Table 1).
Tetherin is an IFN-inducible protein expressed on the cell
surface that prevents the release of HIV-1 virions (Neil et al.,
2008). APOBEC3G is a member of APOBEC3 family of cytidine
deaminase (Sheehy et al., 2002) that is capable of introducing
hypermutations in cDNA during the RT process (Yu et al.,
2004). Although these effectors have not yet been reported to
be involved in modulating the activity of innate sensors, the
actions of APOBEC3 and tetherin are predicted to alter the
type and magnitude of innate immune responses. For instance,
tetherin-expressing HIV-infected cells that accumulate viral
products (including PAMPs) may become a factory for release
of innate cytokines, as well as better antigen presenting cells
or antigen donor cells for bystander DCs. In addition, all HIV-1
restriction factors are expected to modulate adaptive immune
response to HIV-1, by reducing viral antigen load, as well as
enabling the resistant cells to carry out immune functions.
Therefore, immune intervention through exploiting the functions
of appropriate innate HIV-1 effectors may not only result in
reduce viral load, but possibly also in more efficient priming of
T and B cell immune responses.
Although innate intervention in HIV-1-infected individual is
clearly needed to prevent AIDS progression, a robust prophy-
lactic vaccine based on adaptive immune memory response is
irreplaceable with any other type of approach. Prophylactic
vaccine is the only way to provide life-long protection for
possibly millions of people worldwide and is the only way infec-
tious agents have been successfully eradicated by human hands
in the past. Understanding innate sensor pathways capable of
inducing protective immunity to HIV-1 will be a long awaited396 Immunity 37, September 21, 2012 ª2012 Elsevier Inc.and highly impactful contribution an immunologist can make in
the future years to come.
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